Olga Shatnyeva
Research Subjects
Olga Shatnyeva has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Elisa Lázaro-Ibáñez
Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden
2 shared publications - Niek Dekker
Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
2 shared publications - Nikki Salmond
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
2 shared publications - Xabier Osteikoetxea
Department of Genetics, Cell‐ and Immunobiology Semmelweis University Budapest Hungary
2 shared publications Aditya Dhande
NanoView Biosciences Boston Massachusetts USA
1 shared publicationAlexandra Madsen
Genome Engineering Discovery Biology Discovery Sciences BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden
1 shared publication
Latest Publications
- Open Access
Why Extracellular Vesicles Are Attractive Vehicles for RNA-Based Therapies?
Extracellular Vesicles (EVs) are a focus of intense research worldwide, with many groups exploring their potential for both diagnostic and therapeutic applications. Researchers have characterized EVs into various subtypes, modified common surface markers, and developed diverse isolation and purification techniques. Beyond their diagnostic potential, EVs are being engineered as delivery vehicles for various molecules and therapeutics. RNA therapeutics have the potential to be a transformative solution for patients suffering from chronic and genetic disorders and generally targeting undruggable targets. Despite the success of many RNA therapeutics in both in vivo studies and clinical trials, a significant challenge remains in effectively delivering these therapies to the target cells. Many research groups have adopted the use of lipid nanoparticles (LNPs) and other nanocarriers to encapsulate RNA therapeutics, aiming to deliver them as stably as possible to ensure optimal bioavailability and efficacy. While LNPs have proven successful as delivery vehicles, their use is not without drawbacks, such as accumulation within the body. EVs could be a potential solution to many of the problems around LNPs and other nanocarriers.
Open AccessWhy Extracellular Vesicles Are Attractive Vehicles for RNA-Based Therapies?
Extracellular Vesicles (EVs) are a focus of intense research worldwide, with many groups exploring their potential for both diagnostic and therapeutic applications. Researchers have characterized EVs into various subtypes, modified common surface markers, and developed diverse isolation and purification techniques. Beyond their diagnostic potential, EVs are being engineered as delivery vehicles for various molecules and therapeutics. RNA therapeutics have the potential to be a transformative solution for patients suffering from chronic and genetic disorders and generally targeting undruggable targets. Despite the success of many RNA therapeutics in both in vivo studies and clinical trials, a significant challenge remains in effectively delivering these therapies to the target cells. Many research groups have adopted the use of lipid nanoparticles (LNPs) and other nanocarriers to encapsulate RNA therapeutics, aiming to deliver them as stably as possible to ensure optimal bioavailability and efficacy. While LNPs have proven successful as delivery vehicles, their use is not without drawbacks, such as accumulation within the body. EVs could be a potential solution to many of the problems around LNPs and other nanocarriers.
- Open Access
- 18 May 2022
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 11 (5) , e12225
Engineered Cas9 extracellular vesicles as a novel gene editing tool
Extracellular vesicles (EVs) have shown promise as biological delivery vehicles, but therapeutic applications require efficient cargo loading. Here, we developed new methods for CRISPR/Cas9 loading into EVs through reversible heterodimerization of Cas9‐fusions with EV sorting partners. Cas9‐loaded EVs were collected from engineered Expi293F cells using standard methodology, characterized using nanoparticle tracking analysis, western blotting, and transmission electron microscopy and analysed for CRISPR/Cas9‐mediated functional gene editing in a Cre‐reporter cellular assay. Light‐induced dimerization using Cryptochrome 2 combined with CD9 or a Myristoylation‐Palmitoylation‐Palmitoylation lipid modification resulted in efficient loading with approximately 25 Cas9 molecules per EV and high functional delivery with 51% gene editing of the Cre reporter cassette in HEK293 and 25% in HepG2 cells, respectively. This approach was also effective for targeting knock‐down of the therapeutically relevant PCSK9 gene with 6% indel efficiency in HEK293. Cas9 transfer was detergent‐sensitive and associated with the EV fractions after size exclusion chromatography, indicative of EV‐mediated transfer. Considering the advantages of EVs over other delivery vectors we envision that this study will prove useful for a range of therapeutic applications, including CRISPR/Cas9 mediated genome editing.
- 18 May 2022
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 11 (5) , e12225
Open AccessEngineered Cas9 extracellular vesicles as a novel gene editing tool
Extracellular vesicles (EVs) have shown promise as biological delivery vehicles, but therapeutic applications require efficient cargo loading. Here, we developed new methods for CRISPR/Cas9 loading into EVs through reversible heterodimerization of Cas9‐fusions with EV sorting partners. Cas9‐loaded EVs were collected from engineered Expi293F cells using standard methodology, characterized using nanoparticle tracking analysis, western blotting, and transmission electron microscopy and analysed for CRISPR/Cas9‐mediated functional gene editing in a Cre‐reporter cellular assay. Light‐induced dimerization using Cryptochrome 2 combined with CD9 or a Myristoylation‐Palmitoylation‐Palmitoylation lipid modification resulted in efficient loading with approximately 25 Cas9 molecules per EV and high functional delivery with 51% gene editing of the Cre reporter cassette in HEK293 and 25% in HepG2 cells, respectively. This approach was also effective for targeting knock‐down of the therapeutically relevant PCSK9 gene with 6% indel efficiency in HEK293. Cas9 transfer was detergent‐sensitive and associated with the EV fractions after size exclusion chromatography, indicative of EV‐mediated transfer. Considering the advantages of EVs over other delivery vectors we envision that this study will prove useful for a range of therapeutic applications, including CRISPR/Cas9 mediated genome editing.
- Open Access
- 2 August 2021
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 10 (10) , e12130
Quantification of protein cargo loading into engineered extracellular vesicles at single‐vesicle and single‐molecule resolution
Extracellular Vesicles (EVs) have been intensively explored for therapeutic delivery of proteins. However, methods to quantify cargo proteins loaded into engineered EVs are lacking. Here, we describe a workflow for EV analysis at the single‐vesicle and single‐molecule level to accurately quantify the efficiency of different EV‐sorting proteins in promoting cargo loading into EVs. Expi293F cells were engineered to express EV‐sorting proteins fused to green fluorescent protein (GFP). High levels of GFP loading into secreted EVs was confirmed by Western blotting for specific EV‐sorting domains, but quantitative single‐vesicle analysis by Nanoflow cytometry detected GFP in less than half of the particles analysed, reflecting EV heterogeneity. Anti‐tetraspanin EV immunostaining in ExoView confirmed a heterogeneous GFP distribution in distinct subpopulations of CD63+, CD81+, or CD9+ EVs. Loading of GFP into individual vesicles was quantified by Single‐Molecule Localization Microscopy. The combined results demonstrated TSPAN14, CD63 and CD63/CD81 fused to the PDGFRβ transmembrane domain as the most efficient EV‐sorting proteins, accumulating on average 50–170 single GFP molecules per vesicle. In conclusion, we validated a set of complementary techniques suitable for high‐resolution analysis of EV preparations that reliably capture their heterogeneity, and propose highly efficient EV‐sorting proteins to be used in EV engineering applications.
- 2 August 2021
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 10 (10) , e12130
Open AccessQuantification of protein cargo loading into engineered extracellular vesicles at single‐vesicle and single‐molecule resolution
Extracellular Vesicles (EVs) have been intensively explored for therapeutic delivery of proteins. However, methods to quantify cargo proteins loaded into engineered EVs are lacking. Here, we describe a workflow for EV analysis at the single‐vesicle and single‐molecule level to accurately quantify the efficiency of different EV‐sorting proteins in promoting cargo loading into EVs. Expi293F cells were engineered to express EV‐sorting proteins fused to green fluorescent protein (GFP). High levels of GFP loading into secreted EVs was confirmed by Western blotting for specific EV‐sorting domains, but quantitative single‐vesicle analysis by Nanoflow cytometry detected GFP in less than half of the particles analysed, reflecting EV heterogeneity. Anti‐tetraspanin EV immunostaining in ExoView confirmed a heterogeneous GFP distribution in distinct subpopulations of CD63+, CD81+, or CD9+ EVs. Loading of GFP into individual vesicles was quantified by Single‐Molecule Localization Microscopy. The combined results demonstrated TSPAN14, CD63 and CD63/CD81 fused to the PDGFRβ transmembrane domain as the most efficient EV‐sorting proteins, accumulating on average 50–170 single GFP molecules per vesicle. In conclusion, we validated a set of complementary techniques suitable for high‐resolution analysis of EV preparations that reliably capture their heterogeneity, and propose highly efficient EV‐sorting proteins to be used in EV engineering applications.